Re G

2.6k total citations
96 papers, 1.6k citations indexed

About

Re G is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Re G has authored 96 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 57 papers in Pulmonary and Respiratory Medicine and 21 papers in Cancer Research. Recurrent topics in Re G's work include Cancer Treatment and Pharmacology (20 papers), Renal cell carcinoma treatment (18 papers) and Prostate Cancer Treatment and Research (17 papers). Re G is often cited by papers focused on Cancer Treatment and Pharmacology (20 papers), Renal cell carcinoma treatment (18 papers) and Prostate Cancer Treatment and Research (17 papers). Re G collaborates with scholars based in Italy, United States and Malaysia. Re G's co-authors include S. Monfardini, Andrea Veronesi, Angela Buonadonna, S.M.M. Basso, Salvatore Tumolo, Franco Lumachi, Davide Adriano Santeufemia, Giuseppe Toffoli, Erika Cecchin and Enzo Galligioni and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Re G

92 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Re G Italy 20 823 576 513 295 169 96 1.6k
Felix Chu United States 12 632 0.8× 539 0.9× 588 1.1× 260 0.9× 238 1.4× 19 1.7k
Salvatore Tumolo Italy 24 937 1.1× 431 0.7× 299 0.6× 303 1.0× 208 1.2× 106 1.8k
Axel Hegele Germany 23 409 0.5× 709 1.2× 600 1.2× 671 2.3× 246 1.5× 134 1.9k
Victoria M. Chia United States 19 667 0.8× 175 0.3× 324 0.6× 415 1.4× 212 1.3× 36 1.6k
Hervé Curé France 20 1.3k 1.6× 827 1.4× 279 0.5× 218 0.7× 510 3.0× 52 2.3k
Marie‐Elisabeth Toubert France 24 261 0.3× 265 0.5× 215 0.4× 637 2.2× 264 1.6× 63 2.3k
W. Qian United Kingdom 18 703 0.9× 406 0.7× 244 0.5× 532 1.8× 143 0.8× 39 1.8k
John Hohneker United States 23 1.5k 1.8× 496 0.9× 290 0.6× 171 0.6× 263 1.6× 40 1.9k
Joost R.M. van der Sijp Netherlands 27 453 0.6× 244 0.4× 194 0.4× 500 1.7× 214 1.3× 39 1.5k
Dieter Koeberle Switzerland 23 1.6k 2.0× 739 1.3× 271 0.5× 562 1.9× 430 2.5× 87 2.3k

Countries citing papers authored by Re G

Since Specialization
Citations

This map shows the geographic impact of Re G's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Re G with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Re G more than expected).

Fields of papers citing papers by Re G

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Re G. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Re G. The network helps show where Re G may publish in the future.

Co-authorship network of co-authors of Re G

This figure shows the co-authorship network connecting the top 25 collaborators of Re G. A scholar is included among the top collaborators of Re G based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Re G. Re G is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Santeufemia, Davide Adriano, Giuseppe Palmieri, Gianmaria Miolo, et al.. (2023). Current Trends in Mucosal Melanomas: An Overview. Cancers. 15(5). 1356–1356. 14 indexed citations
2.
Aglietta, Massimo, Vanna Chiarion‐Sileni, Paolo Fava, et al.. (2021). Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy). Targeted Oncology. 16(6). 789–799. 5 indexed citations
3.
Zattoni, Fabio, Alessandro Morlacco, Fabio Matrone, et al.. (2019). Multimodal treatment for high-risk locally-advanced prostate cancer following radical prostatectomy and extended lymphadenectomy. Minerva Urologica e Nefrologica. 71(5). 508–515. 5 indexed citations
4.
Caggiari, Laura, Gianmaria Miolo, Angela Buonadonna, et al.. (2017). Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype. International Journal of Molecular Sciences. 19(1). 47–47. 12 indexed citations
5.
Ferrara, Gerardo, et al.. (2016). Epidermotropic progression of melanoma during therapy with dabrafenib and trametinib. Journal of the American Academy of Dermatology. 75(4). e133–e135. 1 indexed citations
6.
7.
8.
Corradin, Maria Teresa, et al.. (2014). In situ malignant melanoma on nevus spilus in an elderly patient.. PubMed. 23(1). 17–9. 5 indexed citations
9.
Giorgi, Ugo De, Karim Rihawi, Michele Aieta, et al.. (2014). Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. Journal of Geriatric Oncology. 5(2). 156–163. 22 indexed citations
10.
Fusco, Vittorio, Camillo Porta, Giorgia Saia, et al.. (2014). Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature. Clinical Genitourinary Cancer. 13(4). 287–294. 44 indexed citations
11.
Donini, Maddalena, Sebastiano Buti, Silvia Lazzarelli, et al.. (2014). Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg). Targeted Oncology. 10(2). 277–286. 9 indexed citations
12.
Buti, Sebastiano, Silvia Lazzarelli, Cecilia Simonelli, et al.. (2010). Dose-finding Trial of a Combined Regsimen With Bevacizumab, Immunotherapy, and Chemotherapy in Patients With Metastatic Renal Cell Cancer: An Italian Oncology Group for Clinical Research (GOIRC) Study. Journal of Immunotherapy. 33(7). 735–741. 9 indexed citations
13.
Tumolo, Salvatore, et al.. (2001). Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer. Lung Cancer. 34. 37–46. 1 indexed citations
14.
Veronesi, Andrea, et al.. (1996). Multidrug Chemotherapy in theTreatment of Non-Elderly Patients withHormone-Refractory ProstaticCarcinoma. European Urology. 29(4). 434–438. 15 indexed citations
15.
G, Re, Vincenzo Canzonieri, Andrea Veronesi, et al.. (1994). Extrapulmonary small cell carcinoma: A single-institution experience and review of the literature. Annals of Oncology. 5(10). 909–913. 86 indexed citations
16.
Zagonel, Vittorina, Umberto Tirelli, Diego Serraino, et al.. (1994). The Aged Patient with Lung Cancer. Drugs & Aging. 4(1). 34–46. 16 indexed citations
17.
Frustaci, S., Andrea Freschi, Re G, et al.. (1992). Feasibility and efficacy of arginine 2-mercaptoethanesulfonate (ARGIMESNA) in the prevention of hemorragic cystitis from ifosfamide (IFO). Annals of Oncology. 3. S115–S118. 2 indexed citations
18.
Crivellari, Diana, Enzo Galligioni, S. Frustaci, et al.. (1990). Cisplatin and Mitomycin C in Advanced Chemotherapy-Refractory Breast Cancer. Tumori Journal. 76(3). 234–237. 4 indexed citations
19.
Nobile, Maria Teresa, Luciano Canobbio, Enzo Galligioni, et al.. (1988). A Randomized Trial of 5-Fluorouracil Alone Versus 5-Fluorouracil and High Dose Leucovorin in Untreated Advanced Colorectal Cancer Patients. Advances in experimental medicine and biology. 244. 213–218. 16 indexed citations
20.
Galligioni, Enzo, Luciano Canobbio, F. Figoli, et al.. (1987). Cisplatin and 5-fluorouracil combination chemotherapy in advanced and/or metastatic colorectal carcinoma: A phase II study. European Journal of Cancer and Clinical Oncology. 23(6). 657–661. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Felix Chu Breakdown of academic impact, for papers by Salvatore Tumolo Breakdown of academic impact, for papers by Axel Hegele Breakdown of academic impact, for papers by Victoria M. Chia Breakdown of academic impact, for papers by Hervé Curé Breakdown of academic impact, for papers by Marie‐Elisabeth Toubert Breakdown of academic impact, for papers by W. Qian Breakdown of academic impact, for papers by John Hohneker Breakdown of academic impact, for papers by Joost R.M. van der Sijp Breakdown of academic impact, for papers by Dieter Koeberle
Rankless by CCL
2026